- Home
- AMRN vs DSGN Comparison
AMRN vs DSGN Comparison
Compare AMRN & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMRN
- DSGN
- Stock Information
- Founded
- AMRN 1989
- DSGN 2017
- Country
- AMRN Ireland
- DSGN United States
- Employees
- AMRN N/A
- DSGN N/A
- Industry
- AMRN Biotechnology: Pharmaceutical Preparations
- DSGN Biotechnology: Pharmaceutical Preparations
- Sector
- AMRN Health Care
- DSGN Health Care
- Exchange
- AMRN Nasdaq
- DSGN Nasdaq
- Market Cap
- AMRN 216.0M
- DSGN 224.8M
- IPO Year
- AMRN 1993
- DSGN 2021
- Fundamental
- Price
- AMRN $10.41
- DSGN $3.50
- Analyst Decision
- AMRN Sell
- DSGN Hold
- Analyst Count
- AMRN 2
- DSGN 1
- Target Price
- AMRN $7.00
- DSGN $4.00
- AVG Volume (30 Days)
- AMRN 116.9K
- DSGN 140.5K
- Earning Date
- AMRN 05-07-2025
- DSGN 05-07-2025
- Dividend Yield
- AMRN N/A
- DSGN N/A
- EPS Growth
- AMRN N/A
- DSGN N/A
- EPS
- AMRN N/A
- DSGN N/A
- Revenue
- AMRN $214,112,000.00
- DSGN N/A
- Revenue This Year
- AMRN N/A
- DSGN N/A
- Revenue Next Year
- AMRN $0.89
- DSGN N/A
- P/E Ratio
- AMRN N/A
- DSGN N/A
- Revenue Growth
- AMRN N/A
- DSGN N/A
- 52 Week Low
- AMRN $7.00
- DSGN $2.60
- 52 Week High
- AMRN $20.60
- DSGN $7.77
- Technical
- Relative Strength Index (RSI)
- AMRN 53.84
- DSGN 42.85
- Support Level
- AMRN $9.44
- DSGN $3.23
- Resistance Level
- AMRN $11.44
- DSGN $5.04
- Average True Range (ATR)
- AMRN 0.85
- DSGN 0.48
- MACD
- AMRN -0.01
- DSGN -0.05
- Stochastic Oscillator
- AMRN 47.09
- DSGN 15.06
About AMRN Amarin Corporation plc
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.